Group 1 - CRO concept stocks have collectively rebounded, indicating a positive trend in the sector [1] - Tigermed (03347.HK) increased by 9.19%, reaching HKD 39.92 [1] - WuXi AppTec (02359.HK) rose by 4.43%, trading at HKD 106 [1] - Kanglong Chemical (03759.HK) saw a 4.15% increase, priced at HKD 21.58 [1] - WuXi Biologics (02269.HK) experienced a 3.27% rise, with a price of HKD 31.56 [1]

Core Insights - The Hong Kong stock market indices saw significant gains in the afternoon, with the Hang Seng Index rising over 2%, the Hang Seng Tech Index increasing by 2.7%, and the Hang Seng China Enterprises Index up by 1.8% [1] Company Performance - Kuaishou (快手-W) experienced a rise of 6.56% with a year-to-date increase of 66.79%, and a total market capitalization of 294.57 billion [2] - NetEase (网易-S) increased by 6.26%, with a year-to-date gain of 61.57%, and a market cap of 688.29 billion [2] - Alibaba (阿里巴巴-W) rose by 5.42%, showing a year-to-date increase of 93.41%, with a total market value of 2.97 trillion [2] - WuXi AppTec (药明康德) saw a 4.14% increase, with a year-to-date rise of 93.30%, and a market capitalization of 315.38 billion [2] - Baidu (百度集团-SW) increased by 4.10%, with a year-to-date gain of 35.07%, and a market cap of 307.19 billion [2] - Hansoh Pharmaceutical (翰森制药) rose by 4.03%, with a remarkable year-to-date increase of 134.85%, and a market capitalization of 240.51 billion [2] - Zhongsheng Holdings (中升控股) increased by 3.58%, but has a year-to-date decline of 12.81%, with a market cap of 27.41 billion [2] - China Overseas Development (中国海外发展) rose by 3.37%, with a year-to-date increase of 19.16%, and a market cap of 154.54 billion [2] - Longfor Group (龙湖集团) increased by 3.54%, with a year-to-date rise of 6.20%, and a market cap of 72.18 billion [2] - BYD (比亚迪股份) rose by 3.34%, with a year-to-date increase of 9.64%, and a market cap of 873.88 billion [2] - WuXi Biologics (药明生物) increased by 3.34%, with a year-to-date rise of 79.84%, and a market cap of 129.71 billion [2] - Midea Group (美的集团) rose by 2.92%, with a year-to-date increase of 26.14%, and a market cap of 690.12 billion [2] - Meituan (美团-W) increased by 2.88%, but has a year-to-date decline of 35.20%, with a market cap of 600.76 billion [2] - Alibaba Health (阿里健康) rose by 2.87%, with a year-to-date increase of 72.59%, and a market cap of 92.68 billion [2]

Group 1 - The CRO sector is experiencing a collective rebound, with notable stock price increases for companies such as Tigermed (up 9.19% to HKD 39.92), WuXi AppTec (up 4.43% to HKD 106), and others [1] - Citing a recovery in capital market financing activities and an expansion in the overseas trading scale of innovative drugs, the outlook for CXO companies' performance in the second half of the year is optimistic [1] - Morgan Stanley notes that since mid-September, healthcare stocks have been under pressure as investors take profits, but the fundamentals for WuXi's companies remain strong, making their valuations more attractive [1] Group 2 - WuXi AppTec is highlighted as a top pick due to its raised earnings guidance and significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The projected compound annual growth rates for WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Group 1 - CRO concept stocks have collectively rebounded, with notable increases in share prices: Tigermed (300347) up 9.19% to HKD 39.92, WuXi AppTec (603259) up 4.43% to HKD 106, and others showing similar gains [1] - CMB International believes that the recovery of capital market financing activities, expansion of overseas transactions for innovative drugs, and a rebound in domestic R&D demand will lead to a recovery in CXO companies' performance in the second half of the year [1] - Morgan Stanley reports that healthcare stocks have been sold off since mid-September, with investors taking profits while awaiting signals for next year's performance [1] Group 2 - Morgan Stanley highlights that WuXi AppTec's fundamentals remain strong, making its valuation more attractive, especially as the company has raised its earnings guidance and is expanding capacity significantly [1] - The projected compound annual growth rates for earnings from WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiaries from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Core Insights - The CXO sector in A-shares has shown resilience, with 20 out of 29 listed companies reporting year-on-year revenue growth in the first three quarters [1] - The growth in the CXO sector is driven by internationalization and increased demand for innovative drugs, benefiting companies in the upstream of the innovative drug industry chain [1] - The innovative drug sector is experiencing a dual boost from policy support and surging demand, which is stimulating new drug research and development [1] Summary by Categories Industry Trends - Three major trends are emerging in the innovative drug field: 1. Deepening internationalization with an expected 103 license-out transactions and upfront payments reaching $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2] 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a directory for innovative drugs under commercial insurance for the first time [2] 3. Continuous technological breakthroughs in areas such as ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2] Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing [2] - There is significant recovery in the upstream industry chain, with ample room for increasing domestic production rates, driven by smart, digital production and international expansion [2] Key Companies - Leading companies in the CXO sector include: - Kelaiying (002821) (06821) - Kanglong Chemical (300759) (03759) - Zhaoyan New Drug (603127) (06127) - WuXi Biologics (02269) - WuXi AppTec (603259) (02359) [3]

Core Viewpoint - The recent performance of the Hong Kong stock market, particularly in the technology sector, has been influenced by tightening U.S. dollar liquidity and concerns over AI market dynamics, leading to a mixed outlook for future investments [3][5]. Group 1: Market Performance - On November 24, the Hong Kong Stock Connect Technology ETF (159125) saw a sharp increase of 1.86%, with major constituents like Li Auto rising over 6%, and Kuaishou-W and Alibaba-W both increasing by more than 4% [1]. - The Hang Seng Index has experienced significant fluctuations, with historical data indicating an average maximum decline of approximately 17% during major pullbacks, typically lasting around 53 trading days [6]. Group 2: Economic Indicators - Recent U.S. economic data, including a non-farm payroll increase of 119,000 in September, has been mixed, with an unemployment rate rising to 4.4%, impacting the Federal Reserve's interest rate decisions [3]. - The market's expectation for a 25 basis point rate cut in December has decreased to 40%, reflecting a cautious approach from the Federal Reserve amid tight dollar liquidity [4][5]. Group 3: Investment Sentiment - According to Huatai Securities, the Hong Kong sentiment index stood at 35.8 as of November 21, indicating a pessimistic outlook but suggesting that the market may be entering a phase for potential accumulation by left-side investors [7]. - The Hong Kong market is seen as having unique investment opportunities, particularly in AI-related assets, which are expected to align with ongoing industrial trends and support future market performance [9]. Group 4: Sector Analysis - The Hong Kong Stock Connect Technology ETF tracks the Guozheng Hong Kong Stock Connect Technology Index, selecting 30 leading companies with high market capitalization and rapid revenue growth, including Tencent, Alibaba, and BYD [9].

Market Performance - The Hang Seng Index closed at 25,220, down 2.38% for the day and up 25.72% year-to-date [1] - The Hang Seng Tech Index fell 3.21% to 5,395, with a year-to-date increase of 20.76% [1] - The CSI 300 Index decreased by 2.44% to 4,453, with a year-to-date rise of 13.18% [1] - The Shanghai Composite Index closed at 3,834, down 2.45%, marking a year-to-date increase of 14.41% [1] - The Shenzhen Component Index dropped 3.41% to 12,538, with a year-to-date increase of 20.39% [1] Currency and Commodity Overview - The Renminbi Index stood at 97.830, up 0.52% over the past month and 1.35% over six months [2] - Brent crude oil price was $62.720 per barrel, up 2.62% month-on-month but down 1.29% over six months [2] - Gold price was $4,059.66 per ounce, down 1.68% month-on-month but up 22.36% over six months [2] - Bitcoin price fell to $83,560, marking a 7.02% decline, the lowest in over seven months [23] Hong Kong Stock Market Review - The Hong Kong stock market experienced significant declines, with the Hang Seng Index hitting a two-and-a-half-month low and recording its largest single-day drop in over seven months [5] - Major tech stocks like Alibaba and Baidu fell nearly 5%, while Meituan and JD.com dropped close to 3% [5] - The property sector saw significant declines, with Link REIT dropping about 7.5%, marking a near seven-month low [5] A-Share Market Review - The A-share market saw major indices drop between 2.5% to 4%, with the Shanghai Composite Index falling below 3,900 points [6] - The Shenzhen Component Index and ChiNext Index also reached approximately two-and-a-half-month lows [6] US Stock Market Overview - The US stock market indices closed up nearly 1%, with the Dow Jones rising 1.1% to 46,245 [7] - The Nasdaq Index increased by 0.9% to 22,273, while the S&P 500 rose by nearly 1% to 6,602 [7] - Major tech stocks showed mixed results, with Alphabet rising over 3% while Nvidia and Microsoft fell [7] European Market Overview - European stock markets showed mixed results, with the DAX Index down 0.8% and the CAC Index up slightly [8] - Over the week, German stocks fell nearly 3.3%, while French stocks declined close to 2.3% [8] Economic Indicators - The Central City Leading Index (CCL) in Hong Kong rose 0.54% week-on-week, reaching a near one-and-a-half-year high, with a year-to-date increase of 3.52% [11] - In mainland China, electricity consumption in October reached 857.2 billion kWh, a year-on-year growth of 10.4% [20] - Japan's exports to the US have declined for seven consecutive months, with a 3.1% year-on-year drop in October [19]

Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.38%, Green Power Environmental (01330) at 69.48%, and Da Zhong Public Utilities (01635) at 69.45% [1][2] - Alibaba-W (09988), Xiaomi Group-W (01810), and the Tracker Fund of Hong Kong (02800) saw the largest increases in holding amounts over the last five trading days, with increases of +70.62 billion, +33.67 billion, and +15.78 billion respectively [1][2] - WuXi Biologics (02269), China Shenhua (01088), and China Mobile (00941) experienced the largest decreases in holding amounts over the same period, with decreases of -6.43 billion, -3.93 billion, and -3.75 billion respectively [1][3] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding of 100.45 billion shares, representing 72.38% [2] - Green Power Environmental (01330) has a holding of 2.81 billion shares, representing 69.48% [2] - Da Zhong Public Utilities (01635) has a holding of 3.71 billion shares, representing 69.45% [2] Group 2: Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +70.62 billion in holding amount, with a change of +47.84 million shares [2] - Xiaomi Group-W (01810) experienced an increase of +33.67 billion, with a change of +88.41 million shares [2] - The Tracker Fund of Hong Kong (02800) had an increase of +15.78 billion, with a change of +62.24 million shares [2] Group 3: Recent Decreases in Holdings - WuXi Biologics (02269) had a decrease of -6.43 billion in holding amount, with a change of -21.06 million shares [3] - China Shenhua (01088) saw a decrease of -3.93 billion, with a change of -9.94 million shares [3] - China Mobile (00941) experienced a decrease of -3.75 billion, with a change of -4.36 million shares [3]

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].